Vemurafenib is approved for treating metastatic melanoma. It works by inhibiting the activity of BRAF, a protein which, when mutated, drives the growth of metastatic melanoma. Vemurafenib is approved specifically for adult patients with a BRAF mutation called V600.
Vemurafenib has not been assessed in patients with melanoma younger than age 18. The purpose of this study is to find the highest dose of vemurafenib that can be given safely in adolescents (age 12-17) with inoperable stage IIIC/IV melanoma that contains a V600 BRAF mutation.